샘플 요청 목록

 카트 문의
시장보고서
상품코드
1758041

세계의 조류인플루엔자 치료 시장

Bird Flu Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 285 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 조류인플루엔자 치료 시장은 2030년까지 346억 달러에 달할 전망

2024년에 249억 달러로 추정되는 세계의 조류인플루엔자 치료 시장은 2024-2030년의 분석 기간에 CAGR 5.6%로 성장하며, 2030년에는 346억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 항바이러스 치료는 CAGR 5.0%를 기록하며, 분석 기간 종료까지 138억 달러에 달할 것으로 예측됩니다. 병용 치료 부문의 성장률은 분석 기간 중 CAGR 4.7%로 추정됩니다.

미국 시장은 68억 달러로 추정, 중국은 CAGR 8.8%로 성장 예측

미국의 조류인플루엔자 치료 시장은 2024년에 68억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 8.8%로 추이하며, 2030년에는 69억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.8%와 5.5%로 예측됩니다. 유럽에서는 독일이 CAGR 3.6%로 성장할 것으로 예측됩니다.

세계의 조류인플루엔자 치료 시장 - 주요 동향과 촉진요인 정리

조류 인플루엔자 치료가 세계 공중 보건 및 바이오의약품 혁신의 시급한 초점인 이유는 무엇인가?

H5N1, H7N9 등 A형 인플루엔자 바이러스에 의해 발생하는 조류 인플루엔자는 주로 조류에 감염되지만, 감염된 동물과의 밀접한 접촉이나 오염된 환경으로 인해 사람에게도 감염될 수 있습니다. 감염된 동물과의 밀접한 접촉이나 오염된 환경을 통해 인간에게 감염될 수 있는 능력을 가지고 있습니다. 인간에게 감염되는 경우는 비교적 드물지만, 특히 고병원성 조류인플루엔자(HPAI) 균주의 경우 심각한 호흡기 질환을 유발하고 높은 사망률을 보이는 경우가 많습니다. 아시아, 유럽, 아프리카, 북미 및 남미에서 조류인플루엔자가 반복적으로 발생함에 따라 효과적인 조류인플루엔자 치료와 신속한 대응 전략에 대한 수요가 그 어느 때보다 높아지고 있습니다. 조류 인플루엔자 바이러스의 인수공통전염병적 특성(동물에서 사람으로 감염될 수 있는 능력)은 과거 인플루엔자 대유행에서 입증된 바와 같이 심각한 대유행 위험을 초래할 수 있습니다. 또한 조류 인플루엔자 바이러스의 약물 내성 균주 증가와 유전자 변이의 확산은 치료 노력을 복잡하게 만들고, 새로운 항바이러스제, 치료 항체 및 지지요법 프로토콜 개발의 시급성을 강조하고 있습니다. 치료에는 일반적으로 오셀타미비르나 자나미비르와 같은 뉴라미니다제 억제제가 사용되지만, 그 효과는 균주 및 투여 시기에 따라 달라집니다. 약리학적 개입 외에도 산소 공급, 수액 관리, 중증 환자의 경우 인공호흡과 같은 지지요법이 중요합니다. 조류 인플루엔자 치료 시장은 단순한 의료 문제가 아니라 전 세계 바이오 보안 및 전염병 대응 전략의 중요한 요소입니다.

과학 기술의 발전은 조류 독감 치료제의 상황을 어떻게 변화시키고 있는가?

과학과 기술의 혁신은 치료법의 효과와 전망을 확대함으로써 조류독감 치료의 미래를 바꾸는 데 있으며, 매우 중요한 역할을 하고 있습니다. 오셀타미비르(타미플루)와 자나미비르(리렌자)와 같은 전통적인 항바이러스제물이 여전히 1차 선택 약물로 사용되고 있지만, 특정 H5 및 H7 균주의 내성 증가로 인해 새로운 약물 계열과 병용 요법의 개발이 요구되고 있습니다. 연구자들은 현재 중합효소 억제제, 단클론 항체, 바이러스 복제에 관여하는 세포 경로를 표적으로 하는 숙주 지향적 치료제를 모색하고 있으며, COVID-19 백신의 성공에서 영감을 얻은 mRNA 기반 치료제는 맞춤형 단백질 항원 및 면역 조절 성분을 사용하여 새로운 조류 인플루엔자 균주를 신속하게 표적으로 하는 조류 인플루엔자 균주를 신속하게 표적으로 삼기 위해 적용되고 있습니다. 항바이러스제 외에도 회복기 혈장 요법 및 면역글로불린 치료는 중증 감염시 환자의 회복을 촉진하는 능력에 대해 연구되고 있습니다. 진단의 발전, 특히 RT-PCR 및 CRISPR 기반 치료 시점 진단 툴와 같은 분자진단은 감염을 조기에 발견하고 적시에 치료를 시작하여 합병증을 줄이는 데 필수적인 요소이며, AI 및 생물정보학은 바이러스의 진화를 매핑하고 돌연변이 패턴을 예측하는 데 활용되고 있습니다. 미래를 내다보고 치료법을 설계하고, 전 세계 비축 전략을 안내하는 데에 활용되고 있습니다. 또한 전 세계 보건 기관과 제약회사들의 협력으로 조류독감 치료제의 임상시험 및 승인 절차가 가속화되고 있습니다. 이러한 기술 혁신은 임상 결과를 개선할 뿐만 아니라, 향후 조류 인플루엔자 발생에 보다 민첩하고 효과적으로 대응할 수 있는 의료 시스템을 마련하고 있습니다.

조류독감 치료 및 대비를 선도하고 있는 세계 시장과 의료 시스템은?

조류 인플루엔자 치료 및 발병 대응을 위한 노력은 가금류 밀도가 높고, 과거 조류 인플루엔자가 발생한 적이 있으며, 의료 인프라가 잘 갖추어진 지역에 집중되어 있습니다. 중국, 베트남, 인도네시아, 태국을 포함한 동아시아 및 동남아시아 국가들은 야생조류와 가금류 모두에서 조류인플루엔자가 자주 발생하므로 감시 및 치료법 개발의 최전선에 있습니다. 특히 중국은 H7N9의 대규모 발생 이후 조류독감 조사, 진단, 백신 제조에 많은 투자를 하고 있습니다. 일본과 한국도 조기 발견, 항바이러스제 비축, 공중보건 조정을 결합한 통합 전략으로 주목할 만합니다. 북미에서는 미국과 캐나다가 CDC와 미국 농무부와 같은 기관의 지도 아래 신속한 대응, 항바이러스제 배포, 전략적 국가 비축에 중점을 둔 탄탄한 준비 체계를 유지하고 있습니다. 미국 바이오메디컬첨단연구개발국(BARDA)은 민관 파트너십과 연방정부의 자금 지원을 통해 조류독감 치료제의 연구개발을 지원하고 있습니다. 영국, 프랑스, 독일 등의 국가가 주도하는 유럽에서는 인수공통전염병의 위협을 관리하기 위해 인간, 동물, 환경 위생 감시를 통합한 원헬스 접근법을 강조하고 있습니다. 한편, WHO, FAO, OIE(현 세계동물보건기구)와 같은 국제기구는 세계 대응의 조정, 기술지도, 개발도상국의 치료 접근성 지원에서 중심적인 역할을 하고 있습니다. 사하라 사막 이남의 아프리카와 남미 일부 지역은 새로운 우려 지역으로, 제한된 의료 인프라는 도전이 되기도 하지만 동시에 표적화된 개입과 역량 개발의 기회가 되기도 합니다. 이 모든 지역에서 조류 인플루엔자의 영향을 완화하고 더 광범위한 건강 위기로 확산되는 것을 막기 위해서는 치료 프로토콜과 실시간 발병 정보 및 정책 프레임워크를 통합하는 것이 필수적입니다.

세계 조류독감 치료제 시장의 성장을 가속하는 요인은 무엇인가?

세계 조류 인플루엔자 치료제 시장의 성장은 역학적 긴급성, 과학적 발전, 정책적 초점, 전염병 대책에 대한 투자 증가가 복합적으로 작용하고 있습니다. 선진국과 신흥 국가에서 고병원성 조류 인플루엔자가 반복적으로 발생하면서 신속하고 효과적인 치료법의 필요성에 대한 전 세계 인식이 높아지고 있습니다. 조류 인플루엔자 균주가 돌연변이를 일으켜 인간에게 대유행을 일으킬 수 있으므로 특히 조류 인플루엔자 균주가 인간에서 인간으로 지속적인 감염 능력을 획득할 경우, 치료제 개발은 공중 보건 기관과 제약사 모두에게 최우선 과제가 되고 있습니다. 국가 비축 프로그램, 긴급 사용 허가, 항바이러스제 연구개발 보조금 등 정부의 자금 지원 및 전략적 보건 구상도 중요한 역할을 하고 있으며, mRNA 및 단클론 항체 플랫폼이 다른 바이러스 감염에 성공적으로 대응하고 있으므로 시장 성장의 확고한 기반이 되고 있습니다. 조류독감에 대한 유사한 기술에 대한 관심과 투자가 가속화되고 있습니다. 또한 맞춤형 의료와 정밀의료에 대한 수요 증가는 개인별 면역 반응과 바이러스 아형을 고려한 표적 치료제의 설계에 영향을 미치고 있습니다. 전 세계 여행과 가금류 국제 거래 증가, 도시화로 인해 바이러스 감염의 위험이 증가하고 있으며, 견고한 치료 인프라의 필요성이 더욱 커지고 있습니다. 또한 데이터 분석, 역학 모델링, 디지털 건강 툴의 발전은 발병의 신속한 식별과 합리적인 치료법 배포를 돕고 있습니다. 이러한 요인들을 종합하면 조류독감 치료제 시장은 확대되고 있을 뿐만 아니라, 전염병 위협에 대한 세계 강인성을 구축하는 것을 목표로 하는 보다 광범위한 공중보건 전략에 통합되고 있습니다.

부문

유형(항바이러스 치료, 병용 치료, 예방적 항생제 치료, 리바비린 치료), 최종사용자(진료소 최종사용자, 병원 최종사용자, 기관 보건 센터 최종사용자, 기타 최종사용자)

조사 대상 기업의 예

  • Abbott
  • BioCryst Pharmaceuticals
  • Boehringer Ingelheim
  • Ceva Sante Animale
  • Cipla
  • CSL Limited(Seqirus)
  • Elanco Animal Health
  • Gilead Sciences
  • GlaxoSmithKline(GSK)
  • Hester Biosciences
  • Macleods Pharmaceuticals
  • Merck & Co.
  • Moderna
  • Novavax
  • Pfizer
  • Phibro Animal Health
  • Roche
  • Sanofi
  • Sinovac Biotech
  • Zoetis

AI 통합

우리는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.15

Global Bird Flu Treatment Market to Reach US$34.6 Billion by 2030

The global market for Bird Flu Treatment estimated at US$24.9 Billion in the year 2024, is expected to reach US$34.6 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Antiviral Treatment, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$13.8 Billion by the end of the analysis period. Growth in the Combination Treatment segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.8 Billion While China is Forecast to Grow at 8.8% CAGR

The Bird Flu Treatment market in the U.S. is estimated at US$6.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.9 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Bird Flu Treatment Market - Key Trends & Drivers Summarized

Why Is Bird Flu Treatment an Urgent Focus for Global Public Health and Biopharmaceutical Innovation?

Bird flu, or avian influenza, remains a persistent and evolving threat to both global public health and the poultry industry. Caused by influenza type A viruses such as H5N1, H7N9, and others, bird flu primarily affects birds but has the capacity to infect humans through close contact with infected animals or contaminated environments. Human infections, though relatively rare, often result in severe respiratory illness and a high mortality rate, especially in the case of highly pathogenic avian influenza (HPAI) strains. With repeated outbreaks occurring in Asia, Europe, Africa, and the Americas, the demand for effective bird flu treatments and rapid response strategies has never been greater. The zoonotic nature of the virus-its ability to jump from animals to humans-poses a significant pandemic risk, as evidenced by past influenza pandemics. Moreover, the increasing prevalence of drug-resistant strains and genetic mutations in avian influenza viruses complicate treatment efforts and underline the urgency of developing novel antiviral drugs, therapeutic antibodies, and supportive care protocols. Treatment typically includes neuraminidase inhibitors like oseltamivir and zanamivir, though their effectiveness varies depending on the strain and timing of administration. In addition to pharmacologic interventions, supportive therapies such as oxygen supplementation, fluid management, and, in severe cases, mechanical ventilation, are crucial. The bird flu treatment market is not just a healthcare issue but a critical component of biosecurity and pandemic preparedness strategies worldwide.

How Are Scientific and Technological Advances Transforming the Landscape of Bird Flu Therapeutics?

Scientific innovation is playing a pivotal role in reshaping the future of bird flu treatment by expanding both the effectiveness and scope of therapeutic options. Traditional antiviral drugs such as oseltamivir (Tamiflu) and zanamivir (Relenza) continue to be used as first-line treatments, but growing resistance among certain H5 and H7 strains has prompted the development of new drug classes and combination therapies. Researchers are now exploring polymerase inhibitors, monoclonal antibodies, and host-directed therapies that target cellular pathways involved in viral replication. mRNA-based therapeutics, inspired by the success of COVID-19 vaccines, are being adapted to rapidly target emerging avian influenza strains with customized protein antigens or immune-modulating components. In addition to antivirals, convalescent plasma therapy and immunoglobulin treatments are being investigated for their ability to boost patient recovery during severe infections. Diagnostic advancements, particularly in molecular diagnostics like RT-PCR and CRISPR-based point-of-care tools, allow for early detection of infection and timely initiation of treatment-an essential factor in reducing complications. AI and bioinformatics are being utilized to map viral evolution and predict mutation patterns, supporting the design of future-proof treatments and guiding global stockpiling strategies. Additionally, collaborations between global health organizations and pharmaceutical companies are accelerating clinical trials and the approval process for bird flu therapeutics. These innovations are not only enhancing clinical outcomes but also preparing healthcare systems for a more agile and effective response to future avian influenza outbreaks.

Which Global Markets and Health Systems Are Leading the Effort in Bird Flu Treatment and Preparedness?

Efforts to advance bird flu treatment and outbreak response are concentrated in regions with high poultry density, previous outbreak history, and strong healthcare infrastructure. Countries in East and Southeast Asia-including China, Vietnam, Indonesia, and Thailand-are at the forefront of surveillance and treatment development due to their frequent exposure to bird flu outbreaks in both wild and domesticated bird populations. China, in particular, has invested heavily in avian influenza research, diagnostics, and vaccine production, especially following large-scale outbreaks of H7N9. Japan and South Korea are also notable for their integrated strategies combining early detection, antiviral stockpiling, and public health coordination. In North America, the United States and Canada maintain robust preparedness frameworks under the guidance of agencies like the CDC and USDA, focusing on rapid response, antiviral distribution, and strategic national stockpiles. The U.S. Biomedical Advanced Research and Development Authority (BARDA) supports bird flu treatment R&D through public-private partnerships and federal funding. Europe, led by countries such as the UK, France, and Germany, emphasizes One Health approaches, integrating human, animal, and environmental health surveillance to manage zoonotic threats. Meanwhile, international organizations like the WHO, FAO, and OIE (now WOAH) play a central role in coordinating global responses, providing technical guidance, and supporting treatment accessibility in developing nations. Sub-Saharan Africa and parts of South America are emerging areas of concern, where limited healthcare infrastructure poses challenges but also presents opportunities for targeted intervention and capacity-building. Across all these regions, the integration of treatment protocols with real-time outbreak intelligence and policy frameworks is essential to mitigating the impacts of bird flu and preventing its escalation into a broader health crisis.

What Is Fueling the Growth in the Global Bird Flu Treatment Market?

The growth in the global bird flu treatment market is driven by a combination of epidemiological urgency, scientific advancement, policy focus, and increased investment in pandemic preparedness. The repeated emergence of highly pathogenic avian influenza outbreaks in both developed and developing countries has heightened global awareness of the need for rapid, effective therapeutic options. The potential for bird flu strains to mutate and cause a human pandemic-especially as they acquire capabilities for sustained human-to-human transmission-has made treatment development a top priority for public health agencies and pharmaceutical companies alike. Government funding and strategic health initiatives are also playing a critical role, with national stockpiling programs, emergency use authorizations, and grants for antiviral R&D providing a solid foundation for market growth. The success of mRNA and monoclonal antibody platforms in combating other viral infections has accelerated interest and investment in similar technologies for avian influenza. Additionally, the growing demand for personalized and precision medicine is influencing the design of targeted therapeutics that account for individual immune responses and viral subtypes. The rise of global travel, international poultry trade, and urbanization are increasing the risk of virus transmission, further driving the need for robust treatment infrastructure. Furthermore, advancements in data analytics, epidemiological modeling, and digital health tools are supporting faster identification of outbreaks and streamlined therapeutic deployment. Collectively, these factors are not only expanding the market for bird flu treatments but are also embedding it into broader public health strategies aimed at building global resilience against infectious disease threats.

SCOPE OF STUDY:

The report analyzes the Bird Flu Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment, Ribavirin Treatment); End-Use (Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott
  • BioCryst Pharmaceuticals
  • Boehringer Ingelheim
  • Ceva Sante Animale
  • Cipla
  • CSL Limited (Seqirus)
  • Elanco Animal Health
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Hester Biosciences
  • Macleods Pharmaceuticals
  • Merck & Co.
  • Moderna
  • Novavax
  • Pfizer
  • Phibro Animal Health
  • Roche
  • Sanofi
  • Sinovac Biotech
  • Zoetis

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Bird Flu Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Frequency of Zoonotic Outbreaks Throws the Spotlight on Antiviral and Supportive Therapies for Bird Flu
    • Global Pandemic Preparedness Initiatives Spur Accelerated R&D in Avian Influenza Therapeutics
    • Here's How Government Stockpiling and Emergency Use Authorizations Are Driving Demand for Antiviral Inventories
    • Mutation and Strain Variability in H5N1 and H5N8 Challenge the Development of Broad-Spectrum Treatments
    • Growing Investment in One Health Strategies Strengthens the Business Case for Cross-Species Influenza Therapies
    • Increased Surveillance and Early Detection Capabilities Propel Rapid Response Infrastructure for Treatment Access
    • Public Health Campaigns and Awareness Drive Uptake of Preventive and Post-Exposure Antiviral Treatments
    • Here's the Story: How Repurposed Drugs Like Oseltamivir and Baloxavir Are Gaining Renewed Focus Amid Resurgent Cases
    • Global Veterinary and Human Health Convergence Creates Demand for Dual-Purpose Treatment Protocols
    • Challenges in Viral Resistance and Therapeutic Efficacy Propel Demand for Next-Generation Influenza Inhibitors
    • Expansion of mRNA and DNA Platform Technologies Fuels Future Opportunities in Rapid Therapeutic Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bird Flu Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bird Flu Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bird Flu Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bird Flu Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antiviral Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antiviral Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antiviral Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Combination Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Combination Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Combination Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Prophylactic Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Prophylactic Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Prophylactic Antibiotics Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ribavirin Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ribavirin Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Ribavirin Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Institutional Health Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Institutional Health Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Institutional Health Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Bird Flu Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Bird Flu Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Bird Flu Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Bird Flu Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Bird Flu Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Bird Flu Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Bird Flu Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Bird Flu Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Bird Flu Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Bird Flu Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Bird Flu Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Bird Flu Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Bird Flu Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Bird Flu Treatment by Type - Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Bird Flu Treatment by Type - Percentage Breakdown of Value Sales for Antiviral Treatment, Combination Treatment, Prophylactic Antibiotics Treatment and Ribavirin Treatment for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Bird Flu Treatment by End-Use - Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Bird Flu Treatment by End-Use - Percentage Breakdown of Value Sales for Clinics End-Use, Hospitals End-Use, Institutional Health Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제